Accueil   Diary - News   All news GeNeuro Confirms Potential of Novel pHERV-K Antibodies for ALS

GeNeuro Confirms Potential of Novel pHERV-K Antibodies for ALS

In collaboration with NINDS, Secures Rights

 

 

  • Following successful CRADA collaboration data in preclinical ALS models, GeNeuro exercises option with the National Institute of Neurological Disorders and Stroke (NINDS) to secure worldwide development rights

 

  • GeNeuro launches pHERV-K Env antibody development program, aiming to reach IND by mid-2020

 

Geneva, Switzerland, October 17, 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that following a successful collaboration in preclinical amyotrophic lateral sclerosis (ALS) models, the Company has signed an exclusive worldwide license with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH). The agreement covers the development of an antibody program to block the activity of pHERV-K Env (pathogenic envelope protein of the HERV-K family of Human Endogenous Retroviruses), a potential key factor in the development of ALS.

 

 

Read the press release